TABLE 2.
Determinant factors of cause-specific deaths by calendar period in ALIVE, 1988–2018
| Time-period | Factorsa | HIV and infectious deaths |
Chronic disease deaths |
Drug and violence deaths |
|||
|---|---|---|---|---|---|---|---|
| sHR | 95% CI | sHR | 95% CI | sHR | 95% CI | ||
|
| |||||||
| 1988–97 | Female | 1.13 | 0.85–1.50 | 0.79 | 0.52–1.22 | 0.75 | 0.47–1.18 |
| Black | 1.23 | 0.65–2.32 | 0.52 | 0.34–0.81 | 0.48 | 0.28–0.77 | |
| Ageb | 0.96 | 0.86–1.07 | 1.28 | 1.16–1.42 | 0.92 | 0.79–1.07 | |
| High school education | 1.14 | 0.89–1.45 | 1.08 | 0.79–1.46 | 0.65 | 0.45–0.94 | |
| Active injecting | 0.95 | 0.74–1.21 | 1.11 | 0.81–1.51 | 1.46 | 0.98–2.18 | |
| HIV seropositive | 17.0 | 10.9–26.5 | 0.53 | 0.37–0.75 | 0.87 | 0.60–1.25 | |
| HCV seropositive | 0.80 | 0.40–1.58 | 1.52 | 0.79–2.94 | 1.59 | 0.71–3.57 | |
| 1998–2005 | Female | 0.89 | 0.64–1.23 | 1.10 | 0.75–1.61 | 0.73 | 0.47–1.13 |
| Black | 1.48 | 0.65–3.39 | 0.96 | 0.47–1.96 | 0.38 | 0.21–0.68 | |
| Ageb | 1.04 | 0.93–1.16 | 1.39 | 1.24–1.56 | 0.91 | 0.78–1.06 | |
| High school education | 0.98 | 0.73–1.30 | 1.08 | 0.77–1.51 | 0.96 | 0.66–1.39 | |
| Active injecting | 0.96 | 0.72–1.27 | 1.20 | 0.85–1.70 | 2.05 | 1.41–2.96 | |
| HIV seropositive | 16.3 | 10.1–26.4 | 0.96 | 0.67–1.38 | 1.41 | 0.97–2.04 | |
| HCV seropositive | 2.09 | 0.77–5.64 | 1.05 | 0.54–2.05 | 1.08 | 0.54–2.17 | |
| 2006–18 | Female | 1.82 | 1.14–2.30 | 1.09 | 0.82–1.44 | 0.56 | 0.39–0.81 |
| Black | 2.59 | 1.11–6.08 | 1.06 | 0.66–1.70 | 0.62 | 0.41–0.94 | |
| Ageb | 1.02 | 0.90–1.16 | 1.40 | 1.28–1.54 | 0.97 | 0.88–1.07 | |
| High school education | 0.91 | 0.64–1.30 | 0.82 | 0.90–1.56 | 1.28 | 0.95–1.74 | |
| Active injecting | 1.79 | 1.26–2.54 | 1.18 | 0.89–1.58 | 2.13 | 1.55–2.93 | |
| HIV seropositive | 8.18 | 5.33–12.6 | 1.19 | 0.90–1.56 | 1.54 | 1.11–2.14 | |
| HCV seropositive | 2.34 | 1.26–2.54 | 1.48 | 0.92–2.36 | 1.39 | 1.55–2.93 | |
Bold type indicates statistically significant results (P < 0.05).
Sex, race (black versus other) and high school education was assessed at baseline. Age, active injecting and HIV serostatus were assessed at every visit. HCV serostatus was assessed at baseline and periodically during follow-up. Total percentage of missingness in time-varying covariates was < 3%.
Per 5 years increase in age.
sHR, sub-distribution hazard ratios, sHR were estimated based on multivariables competing-risk regression based on Fine and Gray’s proportional subhazard model. ALIVE = AIDS Linked to the Intravenous Experience study; HCV = hepatitis C virus; sHR = subdistribution hazard ratio; CI = confidence interval.